MIST · Milestone Pharmaceuticals Inc.
Market Cap
$98.15M
Shares
124.50M
Volume · Oct 1
725.59K
Avg daily vol (3M)
1.42M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.82
Open$0.88
Day$0.81–0.90
52W close$0.79–2.95
Avg vol 30d1.4M
Short int18.4M · 14.7% float · 10.6d
Short vol57%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Feb 8, 2027
Est · unconfirmed
· in 18 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$84.01M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-62.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$111.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+68.1%
Year over year · more shares
Price change (1Y)
-56.7%
Trailing year
Short interest
14.7%
Latest settlement · 10.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−46%
below
Price vs 50-day avg
−23%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−31%
trailing
6-month return
−60%
trailing
YTD return
−60%
this year
Relative strength
−72%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.75% of float · ▲ +5.8% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
78 holders — mid 3-yr range
Squeeze score
66
elevated · 0–100
Fundamentals
EPS growth
−12%
Y/Y
Free cash flow
$-49.3M
Balance sheet
$15.9M
net cash
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−46%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.75% of float · ▲ +5.8% MoM · 10.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
78 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 1%
Range high $3
vs 200-day avg -46%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Patients with PSVT on CARDAMYST | 1,300 | through June 30, 2026 | — |
| Scripts for CARDAMYST | 1,500 | through June 30, 2026 | — |
| Unique prescribers | 800 | through June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MIST
this stock
Milestone Pharmaceuticals Inc.
|
$98.15M | -59.6% | — | — | 14.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +540.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MIST | +2.6% | -30.9% | -59.6% | -5.8% | -59.6% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +3.0% | -30.7% | -72.1% | -6.0% | -71.7% |